Anti-TIGIT drugmakers down as Roche's lung cancer drug fails trial

Arcus Biosciences

05/07/2024 13:17

(Updates)
    ** U.S.-listed shares of Israel-based therapy developer
Compugen  CGEN.TA  fall ~3% to $1.62 premarket
    ** Switzerland-based Roche's  ROG.S  drug tiragolumab, which
is part of a new class of drugs known as anti-TIGIT, failed a
lung cancer treatment trial on Thursday
    ** CGEN has colorectal, ovarian and lung cancer treatments
in development that work by acting on the TIGIT receptor, which
suppresses the proliferation and activation of cells of the
immune system
    ** Other anti-TIGIT drugmakers Iteos Therapeutics  ITOS.O 
down 8.6% and Arcus Biosciences  RCUS.N  down 3.5%
    ** Up to last close, CGEN down 15.6%, RCUS down 24.8% and
ITOS up 35% YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))